The rationale for designing the allogeneic GVAX vaccine is that many tumor antigens are commonly expressed among different patients’ cancers, and GM-CSF released by the modified tumor cells induce antigen-presenting cells chemotaxis to the vaccinating tumor, which then phagocytose the tumor cells and present the tumor antigens on MHC class I and II molecules to both CD4+ and CD8+ T cells and thus induce immune-response against the tumor. The gene discussed is CD4; the disease is neoplasm.